Direct Load Tube Collection Kit

No uncapping.
No specimen transfer.

Placeholder image

    Overview

    Package Inserts

    Transform Specimen Processing for COVID Testing

    No uncapping and no specimen transfer. Expedite your SARS-CoV-2* workflow with a collection device that loads directly on the Panther® system. The Direct Load Tube Collection Kit is authorized for use with the Aptima® SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays. 

    Deliver Results Sooner

    Load directly into the Panther System.

    • Directly load alongside specimen types for other assays with true random and continuous access.
    • Non-hazardous lysis buffer reduces risk by inactivating common respiratory viruses, minimizing biosafety needs.
    • Penetrable cap eliminates uncapping and recapping of tube.

    Traditional 8-Step Respiratory Specimen Workflow

    1

    Uncap Collection Tube

     

    2

    Uncap Transfer Tube

     

    3

    Transfer Primary Specimen

     

    4

    Recap Transfer Tube

     

    5

    Recap Collection Tube

     

    6

    Mix Transfer Tube

     

    7

    Uncap Transfer Tube

     

    8

    Load Onto System

     

    Reduce Labor/Costs/Risk with Fewer Steps

    • Eliminate manual uncapping and recapping.
    • One collection kit for nasal and OP swabs.
    • Remove manual specimen transfer steps.
    • Inactivates common respiratory viruses.
    • Reduce human error and repetitive motion injuries.
    • Guanidine free, non-toxic media.
    • Reduce costs for additional consumables.       
    • Penetrable cap serves as additional cross-contamination barrier.
    * The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays have not been FDA cleared or approved; These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima SARS-CoV-2 assay has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay  has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, Flu A and Flu B and not for any other viruses or pathogens. The Aptima SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.